1. Home
  2. CGEM vs CCNE Comparison

CGEM vs CCNE Comparison

Compare CGEM & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$16.13

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Logo CNB Financial Corporation

CCNE

CNB Financial Corporation

HOLD

Current Price

$31.06

Market Cap

922.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
CCNE
Founded
2016
1865
Country
United States
United States
Employees
N/A
950
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
904.7M
922.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CGEM
CCNE
Price
$16.13
$31.06
Analyst Decision
Strong Buy
Buy
Analyst Count
8
2
Target Price
$30.13
$34.50
AVG Volume (30 Days)
956.5K
73.6K
Earning Date
05-11-2026
04-20-2026
Dividend Yield
N/A
2.51%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$23.21
Revenue Next Year
$5.20
$7.00
P/E Ratio
N/A
$11.84
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$21.19
52 Week High
$16.74
$31.80

Technical Indicators

Market Signals
Indicator
CGEM
CCNE
Relative Strength Index (RSI) 62.01 53.88
Support Level $11.92 $29.29
Resistance Level N/A $31.52
Average True Range (ATR) 1.03 0.73
MACD 0.08 0.01
Stochastic Oscillator 89.05 74.13

Price Performance

Historical Comparison
CGEM
CCNE

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About CCNE CNB Financial Corporation

CNB Financial Corp is a Pennsylvania-chartered bank. The bank is a full-service bank engaging in a full range of banking activities and services for individual, business, governmental and institutional customers. These activities and services principally include checking, savings, and time deposit accounts; real estate, commercial, industrial, residential and consumer loans; and a variety of other specialized financial services. Its Private Client Solutions division offers a full range of client services, including private banking and wealth and asset management. The banking segment derives its revenue through the operations as a full-service bank services, including trust and wealth management services, for individual, business, governmental, and institutional customers.

Share on Social Networks: